Literature DB >> 26079385

Junctophilin 3 (JPH3) expansion mutations causing Huntington disease like 2 (HDL2) are common in South African patients with African ancestry and a Huntington disease phenotype.

Amanda Krause1,2, Claire Mitchell1, Fahmida Essop1,2, Susan Tager3,4, James Temlett3,5, Giovanni Stevanin6,7, Christopher Ross8, Dobrila Rudnicki9, Russell Margolis10.   

Abstract

Huntington disease (HD) is a progressive autosomal dominant neurodegenerative disorder, characterized by abnormal movements, cognitive decline, and psychiatric symptoms, caused by a CAG repeat expansion in the huntingtin (HTT) gene on chromosome 4p. A CAG/CTG repeat expansion in the junctophilin-3 (JPH3) gene on chromosome 16q24.2 causes a Huntington disease-like phenotype (HDL2). All patients to date with HDL2 have some African ancestry. The present study aimed to characterize the genetic basis of the Huntington disease phenotype in South Africans and to investigate the possible origin of the JPH3 mutation. In a sample of unrelated South African individuals referred for diagnostic HD testing, 62% (106/171) of white patients compared to only 36% (47/130) of black patients had an expansion in HTT. However, 15% (20/130) of black South African patients and no white patients (0/171) had an expansion in JPH3, confirming the diagnosis of Huntington disease like 2 (HDL2). Individuals with HDL2 share many clinical features with individuals with HD and are clinically indistinguishable in many cases, although the average age of onset and diagnosis in HDL2 is 5 years later than HD and individual clinical features may be more prominent. HDL2 mutations contribute significantly to the HD phenotype in South Africans with African ancestry. JPH3 haplotype studies in 31 families, mainly from South Africa and North America, provide evidence for a founder mutation and support a common African origin for all HDL2 patients. Molecular testing in individuals with an HD phenotype and African ancestry should include testing routinely for JPH3 mutations.
© 2015 Wiley Periodicals, Inc.

Entities:  

Keywords:  African; Huntington; Huntington disease-like; junctophilin; trinucleotide repeat expansion

Mesh:

Substances:

Year:  2015        PMID: 26079385      PMCID: PMC4565761          DOI: 10.1002/ajmg.b.32332

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  59 in total

1.  Huntington's Disease-like 2 (HDL2) in North America and Japan.

Authors:  Russell L Margolis; Susan E Holmes; Adam Rosenblatt; Lisa Gourley; Elizabeth O'Hearn; Christopher A Ross; William K Seltzer; Ruth H Walker; Tetsuo Ashizawa; Astrid Rasmussen; Michael Hayden; Elisabeth W Almqvist; Juliette Harris; Stanley Fahn; Marcy E MacDonald; Jayalakshmi Mysore; Takayoshi Shimohata; Shoji Tsuji; Nicholas Potter; Kazuhiro Nakaso; Yoshiki Adachi; Kenji Nakashima; Thomas Bird; Amanda Krause; Penny Greenstein
Journal:  Ann Neurol       Date:  2004-11       Impact factor: 10.422

2.  A common Fanconi anemia mutation in black populations of sub-Saharan Africa.

Authors:  Neil V Morgan; Fahmida Essop; Ilja Demuth; Thomy de Ravel; Stander Jansen; Marc Tischkowitz; Cathryn M Lewis; Linda Wainwright; Janet Poole; Hans Joenje; Martin Digweed; Amanda Krause; Christopher G Mathew
Journal:  Blood       Date:  2005-01-18       Impact factor: 22.113

3.  Different molecular basis for spinal muscular atrophy in South African black patients.

Authors:  G Stevens; T Yawitch; J Rodda; S Verhaart; A Krause
Journal:  Am J Med Genet       Date:  1999-10-29

Review 4.  Predictive testing for Huntington disease: interpretation and significance of intermediate alleles.

Authors:  A Semaka; S Creighton; S Warby; M R Hayden
Journal:  Clin Genet       Date:  2006-10       Impact factor: 4.438

5.  Huntington's disease--like 2 is associated with CUG repeat-containing RNA foci.

Authors:  Dobrila D Rudnicki; Susan E Holmes; Mark W Lin; Charles A Thornton; Christopher A Ross; Russell L Margolis
Journal:  Ann Neurol       Date:  2007-03       Impact factor: 10.422

6.  Epidemiological and genetic studies of Huntington's disease in the San-in area of Japan.

Authors:  K Nakashima; Y Watanabe; M Kusumi; E Nanba; Y Maeoka; M Nakagawa; M Igo; H Irie; H Ishino; A Fujimoto; J Goto; K Takahashi
Journal:  Neuroepidemiology       Date:  1996       Impact factor: 3.282

7.  A Huntington disease-like neurodegenerative disorder maps to chromosome 20p.

Authors:  F Xiang; E W Almqvist; M Huq; A Lundin; M R Hayden; L Edström; M Anvret; Z Zhang
Journal:  Am J Hum Genet       Date:  1998-11       Impact factor: 11.025

8.  Huntington's disease confirmed by genetic testing in five African families.

Authors:  E Silber; J Kromberg; J A Temlett; A Krause; D Saffer
Journal:  Mov Disord       Date:  1998-07       Impact factor: 10.338

9.  A South African mixed ancestry family with Huntington disease-like 2: clinical and genetic features.

Authors:  Soraya Bardien; Fatima Abrahams; Himla Soodyall; Lize van der Merwe; Jacquie Greenberg; Tinus Brink; Jonathan Carr
Journal:  Mov Disord       Date:  2007-10-31       Impact factor: 10.338

10.  Patients with features similar to Huntington's disease, without CAG expansion in huntingtin.

Authors:  A Rosenblatt; N G Ranen; D C Rubinsztein; O C Stine; R L Margolis; M V Wagster; M W Becher; A E Rosser; J Leggo; J R Hodges; C K ffrench-Constant; M Sherr; M L Franz; M H Abbott; C A Ross
Journal:  Neurology       Date:  1998-07       Impact factor: 9.910

View more
  13 in total

Review 1.  Genetics of Movement Disorders and the Practicing Clinician; Who and What to Test for?

Authors:  Alessio Di Fonzo; Edoardo Monfrini; Roberto Erro
Journal:  Curr Neurol Neurosci Rep       Date:  2018-05-23       Impact factor: 5.081

Review 2.  The role of junctophilin proteins in cellular function.

Authors:  Stephan E Lehnart; Xander H T Wehrens
Journal:  Physiol Rev       Date:  2022-01-10       Impact factor: 37.312

Review 3.  Recent advances in genetics of chorea.

Authors:  Niccolò E Mencacci; Miryam Carecchio
Journal:  Curr Opin Neurol       Date:  2016-08       Impact factor: 5.710

4.  Comparison of the Huntington's Disease like 2 and Huntington's Disease Clinical Phenotypes.

Authors:  David G Anderson; Aline Ferreira-Correia; Filipe B Rodrigues; N Ahmad Aziz; Jonathan Carr; Edward J Wild; Russell L Margolis; Amanda Krause
Journal:  Mov Disord Clin Pract       Date:  2019-03-12

Review 5.  Huntington's Disease, Huntington's Disease Look-Alikes‎, and Benign Hereditary Chorea: What's New?

Authors:  Susanne A Schneider; Thomas Bird
Journal:  Mov Disord Clin Pract       Date:  2016-01-27

Review 6.  Neurogenomics in Africa: Perspectives, progress, possibilities and priorities.

Authors:  Rufus O Akinyemi; Mayowa O Owolabi; Tolulope Oyeniyi; Bruce Ovbiagele; Donna K Arnett; Hemant K Tiwari; Richard Walker; Adesola Ogunniyi; Raj N Kalaria
Journal:  J Neurol Sci       Date:  2016-05-06       Impact factor: 3.181

7.  Genome Wide Association Study Identifies L3MBTL4 as a Novel Susceptibility Gene for Hypertension.

Authors:  Xin Liu; Cheng Hu; Minghui Bao; Jing Li; Xiaoyan Liu; Xuerui Tan; Yong Zhou; Yequn Chen; Shouling Wu; Shuohua Chen; Rong Zhang; Feng Jiang; Weiping Jia; Xingyu Wang; Xinchun Yang; Jun Cai
Journal:  Sci Rep       Date:  2016-08-02       Impact factor: 4.379

8.  Absence of Acanthocytosis in Huntington's Disease-like 2: A Prospective Comparison with Huntington's Disease.

Authors:  David G Anderson; Sergio Carmona; Kubendran Naidoo; Theresa L Coetzer; Jonathan Carr; Dobrila D Rudnicki; Ruth H Walker; Russell L Margolis; Amanda Krause
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2017-12-05

Review 9.  Intrinsic Disorder in Proteins with Pathogenic Repeat Expansions.

Authors:  April L Darling; Vladimir N Uversky
Journal:  Molecules       Date:  2017-11-24       Impact factor: 4.411

10.  Clinical Application of Epilepsy Genetics in Africa: Is Now the Time?

Authors:  Alina I Esterhuizen; Gemma L Carvill; Rajkumar S Ramesar; Symon M Kariuki; Charles R Newton; Annapurna Poduri; Jo M Wilmshurst
Journal:  Front Neurol       Date:  2018-05-02       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.